dc.contributor.author | Hestad, Knut | |
dc.contributor.author | Engedal, Knut | |
dc.contributor.author | Whist, Jon Elling | |
dc.contributor.author | Farup, Per Grønaas | |
dc.date.accessioned | 2017-01-13T12:46:14Z | |
dc.date.available | 2017-01-13T12:46:14Z | |
dc.date.created | 2016-06-29T11:18:50Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Neuropsychiatric Disease and Treatment. 2016, 12 1365-1370. | nb_NO |
dc.identifier.issn | 1176-6328 | |
dc.identifier.uri | http://hdl.handle.net/11250/2427254 | |
dc.description.abstract | Introduction: Depression is considered an independent risk factor for hypertension, particularly for people with recurrent episodes or a long history of depression. Another risk factor for cardiovascular disease is the Apolipoprotein E e4 allele (ApoE e4). The aim of this study was to examine how ApoE e4 was related to blood pressure (BP) in patients with depression and a control group. Methods: A total of 78 patients, 49 with depression and 29 without, all recruited from the same hospital, underwent ApoE e genotyping (24 had at least one ApoE e4 allele) and examination of BP. Results: In the depression group, but not in the control group, both systolic and diastolic BP were significantly higher in patients with ApoE e4 than in those without. The effect of ApoE e4 on BP differed significantly between the two groups. Conclusion: Our findings showed that the effect of ApoE e4 on BP differed between the patients with depression and the control group. In patients with depression, ApoE e4 was associated with an increase in BP. We suggest that patients with depression and ApoE e4-positive status are particularly prone to develop BP elevation. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Dove Medical Press | nb_NO |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | The effect of ApoE e4 on blood pressure in patients with and without depression | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.source.pagenumber | 1365-1370 | nb_NO |
dc.source.volume | 12 | nb_NO |
dc.source.journal | Neuropsychiatric Disease and Treatment | nb_NO |
dc.identifier.doi | 10.2147/NDT.S106933 | |
dc.identifier.cristin | 1364911 | |
dc.description.localcode | © 2016 Hestad et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 / ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php) | nb_NO |
cristin.unitcode | 194,67,40,0 | |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Psykologisk institutt | |
cristin.unitname | Institutt for kreftforskning og molekylær medisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |